


## VALUATION MULTIPLES

**Forward EV / EBITDA Multiples (monthly to 28/02/2022)** Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of February, the sector traded on a forward EV / EBITDA multiple of 10.1x, compared to the ASX200 on 9.5x.



**Average Values and Trading Multiples (values as at 23/03/2022)** Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2022	EV/EBIT FY2022	Price / Earnings FY2022
Aged Care	714	5.8x	11.9x	48.2x
Animal Health	197	10.6x	NA	17.4x
Biotech	120,543	25.4x	30.0x	39.7x
Hospitals & Clinics	46,931	12.4x	16.0x	21.5x
Medical Devices	1,431	39.3x	NA	NA
<b>Healthcare</b>	<b>171,868</b>	<b>13.5x</b>	<b>16.1x</b>	<b>23.2x</b>

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2021. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result. Composition of companies in Sector Dashboards are updated every 6 months. Most recent update: May 2021.

<sup>1</sup> The InterFinancial Healthcare Index set is an unweighted index comprising Healthcare sector related companies trading on the Australian Securities Exchange (ASX). Estimates are sourced from FactSet Research Systems Inc.

## MERGER & ACQUISITION NEWS...

---



Value: AUD 111.21 m

**Panbela Therapeutics**, the United States based biopharmaceutical company engaged in developing therapeutics for pancreatic diseases is to acquire **Cancer Prevention Pharmaceuticals**, the local development stage company pioneering preventative therapeutics in oncology. The consideration is AUD 80.18m, which consist of AUD 20.18m paid in common shares, AUD 60m paid in earnout. The transaction is expected to close by the second quarter of 2022 and is subject to approval of the issuance of securities in the transactions by Panbela's stockholders, and satisfaction of other customary closing conditions.

---



Value: AUD 70.5 m

**Integral Diagnostics**, the Australia based manufacturer of radiology technology has agreed to acquire **Peloton Radiology**, the local Australia-based holding company having interest in companies engaged in providing radiology services. The consideration is AUD 70.5m, which consist of AUD 59.85m paid in cash, AUD 6.65m paid in common shares, AUD 4m paid in earnout. The transaction is subject to relevant regulatory approvals.

---



Value: AUD 987m

**EQT Partners AB**, the private equity firm, through its subsidiary **EQT Infrastructure Investment Fund**, the private equity fund, has agreed to acquire **Stockland Retirement Living**, the Australia based provider of community living services, from **Stockland Corp**, the Australia based owner, developer and manager of retail, residential, retirement living, office and industrial properties. The consideration is AUD 987m. The transaction is expected to close in late Q2 2022, subject to customary conditions and approvals, including the approval of the Foreign Investment Review Board.

---

## UNDER THE MICROSCOPE...

---

- Owners of **GenesisCare**, an Australian provider of cancer and cardiology care, are looking to sell its cardiology business. The business unit generates an annual EBITDA of about AUD 30m on a revenue of AUD 120m.
- **Haemokinesis**, an Australian blood testing business, is set to list on the ASX to raise AUD 17m. Haemokinesis has priced the IPO at AUD 0.20 per share and will list with a market capitalisation of AUD 77.4m
- **Hills Health Solutions**, the Australian provider of nurse call and patient engagement systems, is open to targeted acquisitions and partnerships.
- **Careteq**, an Australian assisted living technology business, is seeking to explore merger and acquisitions (M&A) opportunities.
- UK-based telehealth company **Doctor Care Anywhere** is exploring acquisition opportunities. The company has a market cap of AUD 106m.
- **Vita Group**, the Australian retailer for personalised services via Artisan Aesthetic Clinic, is seeking to expand through prudent acquisitions. The company has a market cap of AUD 46m.
- Australian pharma manufacturer and distributor **Probiotec** is eyeing strategic acquisition opportunities. Probiotec has a market cap of AUD 172m.
- **Apiam Animal Health**, an Australian veterinary services provider, has a strong acquisitions pipeline. The company will continue to assess opportunities based on their strategic and financial merit. Apiam Animal Health has a market cap of AUD 118m.
- **Capitol Health**, an Australia-based diagnostic imaging business, is continuing to pursue value-creative bolt-on acquisitions aligned with its strategic plan. Capitol Health has a market cap of AUD 370m.
- **Australian Clinical Labs**, an Australia-based pathology group, is seeking strategic acquisitions in specialist and general pathology. The company has a market cap of AUD 1.6bn.
- **Healius**, an Australian healthcare business, is thought to be looking for acquisition opportunities. Healius, which has a market capitalisation of AUD 2.6bn, announced that its underlying profit increased 226% to AUD 245.6m
- **Regis Healthcare**, an Australia-based aged-care business, is seeking aged care facility and home care acquisitions. Regis Healthcare has a market cap of USD 413m
- **Integral Diagnostics**, has agreed to acquire Peloton Radiology, an Australian provider of radiology and diagnostic imaging services, for as much as AUD 66.5m
- **Nanosonics**, an Australian inventor of disinfection devices for the healthcare sector, is targeting strategic acquisitions.
- **Sonic Healthcare**, an Australian medical laboratory company, is assessing synergistic acquisitions. Sonic is well positioned to continue to invest in and expand the business with an active pipeline of opportunities under evaluation. The company has a market cap of USD 12bn
- **Pursue Ability**, an Australian disability support provider, is on the lookout to make an acquisition as part of domestic growth plans,

## CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	(07) 3218 9122	<a href="mailto:sdoyle@interfinancial.com.au">sdoyle@interfinancial.com.au</a>
Paul Keehan	Non-Executive Director	(07) 3218 9100	<a href="mailto:pkeehan@interfinancial.com.au">pkeehan@interfinancial.com.au</a>
Anne-Marie Birkill	Non-Executive Director	(07) 3218 9100	
Rhyll Gardner	Non-Executive Director	(07) 3218 9100	
Brad Shaw	Chief Executive Officer	(07) 3218 9100	<a href="mailto:bshaw@interfinancial.com.au">bshaw@interfinancial.com.au</a>
Mark Steinhardt	Director – M&A	(07) 3218 9105	<a href="mailto:msteinhardt@interfinancial.com.au">msteinhardt@interfinancial.com.au</a>
David Hassum	Director	(07) 3218 9108	<a href="mailto:dhassum@interfinancial.com.au">dhassum@interfinancial.com.au</a>
Andrew Wheeler	Director	(07) 3218 9107	<a href="mailto:awheeler@interfinancial.com.au">awheeler@interfinancial.com.au</a>
Simon Brodie	Director	(07) 3218 9100	<a href="mailto:sbrodie@interfinancial.com.au">sbrodie@interfinancial.com.au</a>
Les Jones	Director	(07) 3218 9100	<a href="mailto:ljones@interfinancial.com.au">ljones@interfinancial.com.au</a>
Michael Kakanis	Associate Director	(07) 3218 9106	<a href="mailto:mkakanis@interfinancial.com.au">mkakanis@interfinancial.com.au</a>
Anuk Manchanda	Associate Director	(07) 3218 9100	<a href="mailto:amanchanda@interfinancial.com.au">amanchanda@interfinancial.com.au</a>
Maggie Liu	Associate	(07) 3218 9100	<a href="mailto:mliu@interfinancial.com.au">mliu@interfinancial.com.au</a>
Kaitlin Whitaker	Analyst	(07) 3218 9100	<a href="mailto:kwhitaker@interfinancial.com.au">kwhitaker@interfinancial.com.au</a>

## DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

**Important Disclaimer** – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

**Disclosure.** InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

*InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.*

<p><b>InterFinancial</b> Corporate Finance Limited ABN: 49 136 962 966 AFSL: 341675 Level 2, 201 Charlotte Street GPO Box 975 Brisbane Queensland 4001 (07) 3218 9100 admin@interfinancial.com.au www.interfinancial.com.au</p>	
---	---